Study of Virtual Reality-based Medical Device for Patients with Depressive Disorder

NCT ID: NCT05701345

Last Updated: 2024-11-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 162 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-03-09
• Study Completion Date: 2024-11-01

Brief Summary

This study apply a wearable visual device (HMD)-VR-based software medical device for patients with depressive disorder for 8 weeks.

The investigator would like to confirm evaluate the safety and efficacy of the wearable visual device(HMD)-VR-based software medical device effect of improving depressive disorder in patients.

Detailed Description

Trial subject is a mild and moderate patients diagnosed with depressive disorder The test group is a wearable visual device(HMD)-VR-based software medical device(OMNIFIT DTx-MDD) and patients who have received standard treatment.

The number of subjects is 162(Two groups, 81 people per group, 15% dropout rate included) Participating institutions are five including Catholic University of Korea Seoul ST.

The clinical trial method is as follows. Subjects who are satisfied with all selection/exclusion criteria and agree to participate in clinical trials are classified into groups that combine test software medical devices and standard treatment based on Visit 2 (Baseline) and groups that perform simple standard treatment. After that, necessary tests are performed at 2, 4, 6, and 8 weeks, and changes in depressive disorder and depressive disorder evaluation scale are confirmed, and safety is evaluated.

Conditions

Depressive Disorder; Major Depressive Disorder; Depressive Episode

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

medical device used group

Wearable visual device(HMD)-VR-based software medical device(OMNIFIT DTx-MDD)

Group Type: EXPERIMENTAL

OMNIFIT DTx-MDD

Intervention Type: DEVICE

This software medical device consists of multifaceted interventions (breathing training, cognitive rehabilitation training, binaural beat training, concentration training) that help improve depressive disorder, and is automatically executed for 35 minutes per session

standard treatment

Intervention Type: OTHER

It is based on the Korean Medical Association's clinical treatment guidelines for depression or the Korean Medical Association's Korean Medical Association/Korean Depression Management Association's 2021 guidelines for drug treatment for depression disorders.

Standard treatment will be performed according to the judgment of the attending physician reflecting the clinical situation based on these treatment guidelines.

medical device unused group

Patients receiving only standard treatment

Group Type: PLACEBO_COMPARATOR

standard treatment

Intervention Type: OTHER

It is based on the Korean Medical Association's clinical treatment guidelines for depression or the Korean Medical Association's Korean Medical Association/Korean Depression Management Association's 2021 guidelines for drug treatment for depression disorders.

Standard treatment will be performed according to the judgment of the attending physician reflecting the clinical situation based on these treatment guidelines.

Interventions

OMNIFIT DTx-MDD

This software medical device consists of multifaceted interventions (breathing training, cognitive rehabilitation training, binaural beat training, concentration training) that help improve depressive disorder, and is automatically executed for 35 minutes per session

Intervention Type: DEVICE

standard treatment

It is based on the Korean Medical Association's clinical treatment guidelines for depression or the Korean Medical Association's Korean Medical Association/Korean Depression Management Association's 2021 guidelines for drug treatment for depression disorders.

Standard treatment will be performed according to the judgment of the attending physician reflecting the clinical situation based on these treatment guidelines.

Intervention Type: OTHER

Other Intervention Names

Wearable visual device-based software medical device; Antidepressant

Eligibility Criteria

Inclusion Criteria

1. right-handed men and women

2. If you agree to participate in this clinical trial and voluntarily sign a written consent form

3. If you can understand and cooperate with the contents of this clinical trial

4. If you have a wireless internet(Wifi) environment

5. Diagnosed by a psychiatrist as major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorder 5th edition(DSM-5) or other specified depressive disorder

6. Mild or moderate depressive episodes with a total hdrs score of 7 or more and 24 or less

7. If there was no change in the type and dose of antidepressants and antipsychotics taken within 4 weeks prior to participation in this clinical trial

Exclusion Criteria

1. if you are pregnant

2. Schizophrenia, schizoaffective disorder, schizophrenic disorder, or a psychotic disorder not otherwise classified or diagnosed in the past

3. If you have current bipolar disorder or have been diagnosed with bipolar disorder in your past history

4. Accompanied by organic mental disorder, epilepsy/convulsive disorder

5. Current eating disorders, alcohol and other substance-related disorders, and obsessive-compulsive disorder

6. Uncontrolled and unstable clinically significant physical condition

7. In cases where psychiatric evaluation and maintenance of treatment are difficult due to other serious acute physical illnesses

8. If you have received electroconvulsive therapy and transcranial magnetic stimulation therapy for a current depressive episode

9. Treatment-resistant depressive disorder for which there was no effect even after using two or more antidepressants in sufficient doses and for a sufficient period of time (6 weeks) for the current depressive episode

10. Currently requiring inpatient treatment for a psychiatric disorder other than depressive disorder (ex. alcohol dependence, substance abuse)

11. If the risk of suicide, self-harm, or other harm is judged to be high according to the evaluation of the study director

12. Current depressive episode accompanied by psychotic symptoms

13. Cases in which a therapeutic intervention for a clinical trial cannot be performed due to deterioration of eyesight or hearing

14. Current treatment with mood stabilizers (lithium, valproate, carbamazepine, lamotrigine) for depressive episodes

15. Those who are unable to participate in clinical trials due to the judgment of other researchers

16. Those who cannot read the consent form (ex. illiterate, foreigners)

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Omni C&S

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Youngsup Woo

Role: PRINCIPAL_INVESTIGATOR

Yeouido St. Mary's Hospital

Locations

Inje University Ilsan Palk Hospital

Ilsan, , South Korea

Jeju National University Hospital

Jeju City, , South Korea

Seoul ST. Mary's Hospital

Seoul, , South Korea

Yeouido ST. Mary's Hospital

Seoul, , South Korea

ST. Vincent's Hospital

Suwon, , South Korea

Countries

South Korea

Other Identifiers

OMNI_MDD_01

Identifier Type: -

Identifier Source: org_study_id